SG10201602111VA - Formulations Comprising Methylthioninium Chloride - Google Patents
Formulations Comprising Methylthioninium ChlorideInfo
- Publication number
- SG10201602111VA SG10201602111VA SG10201602111VA SG10201602111VA SG10201602111VA SG 10201602111V A SG10201602111V A SG 10201602111VA SG 10201602111V A SG10201602111V A SG 10201602111VA SG 10201602111V A SG10201602111V A SG 10201602111VA SG 10201602111V A SG10201602111V A SG 10201602111VA
- Authority
- SG
- Singapore
- Prior art keywords
- formulations
- methylthioninium chloride
- methylthioninium
- chloride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41816410P | 2010-11-30 | 2010-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201602111VA true SG10201602111VA (en) | 2016-04-28 |
Family
ID=45418703
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013040357A SG190406A1 (en) | 2010-11-30 | 2011-11-30 | Formulations comprising methylthioninium chloride |
SG10201602111VA SG10201602111VA (en) | 2010-11-30 | 2011-11-30 | Formulations Comprising Methylthioninium Chloride |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013040357A SG190406A1 (en) | 2010-11-30 | 2011-11-30 | Formulations comprising methylthioninium chloride |
Country Status (10)
Country | Link |
---|---|
US (1) | US9192611B2 (en) |
EP (1) | EP2645994B1 (en) |
JP (1) | JP6093707B2 (en) |
CN (1) | CN103379901B (en) |
AU (1) | AU2011334679B2 (en) |
CA (1) | CA2818068C (en) |
ES (1) | ES2655492T3 (en) |
MY (1) | MY163074A (en) |
SG (2) | SG190406A1 (en) |
WO (1) | WO2012072977A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014153444A (en) * | 2013-02-06 | 2014-08-25 | Konica Minolta Inc | Retardation film, polarizing plate, and liquid crystal display |
SI3487505T1 (en) | 2016-07-25 | 2023-10-30 | Wista Laboratories Ltd., | Administration and dosage of diaminophenothiazines |
FR3104438B1 (en) | 2019-12-12 | 2021-11-19 | Univ Bordeaux | FORMULATION FOR METHYLENE BLUE AND PROCESS |
WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
WO2024063700A1 (en) | 2022-09-21 | 2024-03-28 | Yin Sze Loh | Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4880373A (en) | 1988-04-28 | 1989-11-14 | The Upjohn Company | Tablet press |
JPH0840942A (en) * | 1994-07-29 | 1996-02-13 | Kanegafuchi Chem Ind Co Ltd | Drug-release controlled preparation |
GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
JP5186212B2 (en) * | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | Method for chemical synthesis and purification of diaminophenothiazinium compounds such as methylthioninium chloride (MTC) |
DK2322517T3 (en) | 2004-09-23 | 2019-06-11 | Wista Lab Ltd | METHODS FOR CHEMICAL SYNTHESIS AND CLEANING OF DIAMINOPHENOTHIAZINUM COMPOUNDS WITH METHYLTHIONINUMCHLORID (MTC) |
EP1811957B1 (en) * | 2004-10-19 | 2008-11-26 | KRKA, tovarna zdravil, d.d., Novo mesto | Solid pharmaceutical composition comprising donepezil hydrochloride |
EP1919456A2 (en) * | 2005-08-24 | 2008-05-14 | Wyeth a Corporation of the State of Delaware | Bazedoxifene acetate formulations and manufacturing process thereof |
CA2627695A1 (en) * | 2006-01-05 | 2007-07-19 | Teva Pharmaceutical Industries Ltd. | Dry formulations of aripiprazole |
PT2013191E (en) | 2006-03-29 | 2010-10-29 | Wista Lab Ltd | 3,7-diamino-10h-phenothiazine salts and their use |
US20080317678A1 (en) * | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
ES2546819T3 (en) | 2007-10-03 | 2015-09-28 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines |
WO2009060191A2 (en) | 2007-11-05 | 2009-05-14 | Wista Laboratories Ltd. | Systems for clinical trials |
AU2010299574B2 (en) * | 2009-09-24 | 2013-09-26 | Wista Laboratories Ltd. | Process |
-
2011
- 2011-11-30 SG SG2013040357A patent/SG190406A1/en unknown
- 2011-11-30 CA CA2818068A patent/CA2818068C/en active Active
- 2011-11-30 MY MYPI2013001934A patent/MY163074A/en unknown
- 2011-11-30 SG SG10201602111VA patent/SG10201602111VA/en unknown
- 2011-11-30 AU AU2011334679A patent/AU2011334679B2/en active Active
- 2011-11-30 JP JP2013541414A patent/JP6093707B2/en active Active
- 2011-11-30 CN CN201180057700.9A patent/CN103379901B/en active Active
- 2011-11-30 EP EP11802119.5A patent/EP2645994B1/en active Active
- 2011-11-30 US US13/989,953 patent/US9192611B2/en active Active
- 2011-11-30 ES ES11802119.5T patent/ES2655492T3/en active Active
- 2011-11-30 WO PCT/GB2011/001662 patent/WO2012072977A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
AU2011334679A1 (en) | 2013-07-18 |
CA2818068A1 (en) | 2012-06-07 |
CA2818068C (en) | 2019-06-11 |
EP2645994B1 (en) | 2017-11-01 |
EP2645994A2 (en) | 2013-10-09 |
JP6093707B2 (en) | 2017-03-08 |
US9192611B2 (en) | 2015-11-24 |
WO2012072977A8 (en) | 2012-09-20 |
CN103379901A (en) | 2013-10-30 |
ES2655492T3 (en) | 2018-02-20 |
CN103379901B (en) | 2018-04-03 |
MY163074A (en) | 2017-08-15 |
JP2013544272A (en) | 2013-12-12 |
WO2012072977A3 (en) | 2012-08-16 |
SG190406A1 (en) | 2013-06-28 |
WO2012072977A2 (en) | 2012-06-07 |
AU2011334679B2 (en) | 2016-12-15 |
US20130243858A1 (en) | 2013-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2100005I1 (en) | Methylthioninium chloride | |
GB201205984D0 (en) | No details | |
AU334223S (en) | Insole | |
GB201112400D0 (en) | No details | |
IL222637A0 (en) | Alcohol-resistant formulations | |
ZA201206589B (en) | Incotine containing formulation | |
HK1173368A1 (en) | Pigmentation-preventing or-ameliorating agent | |
GB201015822D0 (en) | Medical ruggedised case | |
SG10201602111VA (en) | Formulations Comprising Methylthioninium Chloride | |
PL2359816T3 (en) | Aripiprazole formulations | |
ZA201300194B (en) | Formulations | |
AU332833S (en) | Insole | |
GB201110193D0 (en) | Formulations | |
GB201013513D0 (en) | Formulations | |
GB201202348D0 (en) | No details | |
GB201105908D0 (en) | No details | |
ZA201300196B (en) | Formulations | |
GB201006326D0 (en) | Formulation | |
GB201018648D0 (en) | Formulations | |
GB201018645D0 (en) | Formulations | |
GB201018647D0 (en) | Formulations | |
GB201018649D0 (en) | Formulations | |
GB201012589D0 (en) | Formulations | |
GB201010494D0 (en) | Formulations | |
GB201008470D0 (en) | Formulations |